Financial Performance - The net profit attributable to the parent company for 2024 is -3,443,219,977.05 RMB, indicating a loss [8]. - The company reported an ending undistributed profit of -1,838,384,447.00 RMB as of December 31, 2024 [8]. - The company's revenue for 2024 was approximately ¥80.28 billion, a decrease of 29.21% compared to ¥113.41 billion in 2023 [25]. - The net profit attributable to shareholders for 2024 was approximately -¥3.44 billion, reflecting a decline of 162.30% from ¥5.53 billion in 2023 [25]. - The net cash flow from operating activities for 2024 was approximately ¥8.01 billion, down 66.63% from ¥24.00 billion in 2023 [25]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was -5.232 billion yuan, a decrease of 190.91% year-on-year [126]. - The company's operating revenue for the period was CNY 80.28 billion, a decrease of 29.21% year-on-year [144]. - The operating cost for the period was CNY 72.58 billion, down 24.70% compared to the previous year [144]. - The gross profit margin in the photovoltaic industry was 9.18%, a decrease of 5.48 percentage points compared to the previous year [146]. - The company's financial expenses increased by 264.59% year-on-year, primarily due to increased interest expenses and reduced foreign exchange gains [144]. Shareholder Returns - The total amount of share repurchase in 2024 was 259,827,424.66 RMB, which will be considered as cash dividends for the year [9]. - The company will not distribute cash dividends or conduct capital reserve transfers in 2024 [9]. - The company has not proposed any plans for capital reserve transfers or stock dividends for 2024 [9]. Risk Management - The company has detailed potential risks in the report, which can be found in the "Management Discussion and Analysis" section [6]. - The company emphasizes that forward-looking statements do not constitute a commitment to investors and advises caution regarding investment risks [10]. - The company faces risks related to the potential for significant performance declines or losses due to supply-demand imbalances and trade protectionism in overseas markets [126]. - The company is exposed to risks from fluctuations in raw material prices and logistics costs, which could impact profitability [130]. - The company has ongoing significant litigation or arbitration cases that could adversely affect its operating performance [141]. Audit and Compliance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm [7]. - The board of directors and management have confirmed the authenticity and completeness of the annual report [5]. Research and Development - Research and development expenses accounted for 6.92% of operating revenue, an increase of 2.04 percentage points compared to the previous year [28]. - The total R&D expenditure for the year reached ¥5,557,707,001.55, reflecting a slight increase of 0.49% compared to the previous year [109]. - The company filed for 1,596 new invention patents during the year, bringing the total number of applications to 3,424 [107]. - A total of 724 invention patents were granted this year, increasing the cumulative number of granted patents to 1,117 [107]. - The company has established national-level R&D platforms and is committed to protecting its core technologies from leaks [129]. - The company is enhancing its technological capabilities through significant investments in R&D, maintaining a leading position in the industry [122]. Market Position and Strategy - The company aims to expand its market presence through strategic partnerships and potential acquisitions in the renewable energy sector [25]. - The company is focusing on the development of PERC solar cells, which have a conversion efficiency exceeding 20% [25]. - The company is also investing in TOPCon technology to enhance battery performance and efficiency [25]. - The company maintained growth in component shipments despite a decline in profitability due to falling prices in the photovoltaic component market [28]. - The company has established a multi-business ecosystem that enhances its ability to withstand cyclical fluctuations in the industry [124]. - The company is focusing on expanding its market share in the residential and commercial sectors, with a gradual increase in product offerings [114]. Production and Operations - The company shipped over 70GW of components in 2024, with cumulative shipments of the 210 series components exceeding 170GW, maintaining the industry's leading position [39]. - The company launched the new i-TOPCon Ultra technology and successfully produced the world's first 800W+ stacked component, marking a new era in perovskite/crystalline silicon stacked battery component industrialization [39]. - The company’s energy storage sales exceeded 10GWh across six major regional markets, achieving over 100% growth in installed capacity [45]. - The company’s storage battery and system product capacity reached 16GWh during the reporting period, supporting its global expansion strategy [47]. - The company has successfully developed high-reflective black adhesive films and high-strength silicone, leading to improved performance in harsh weather conditions [93]. Global Expansion - The company has established regional headquarters in Zurich, Silicon Valley, Miami, Singapore, and Dubai, with operations in over 180 countries [120]. - The company is actively expanding its global manufacturing base, including a production facility in Indonesia to mitigate trade risks [123]. - The company is focusing on recycling technologies for photovoltaic components, aiming for 100% recovery of key materials [121]. Technology and Innovation - The company has set a world record for solar cell efficiency at 26.58% with its N-type bifacial i-TOPCon cells, showcasing the potential of TOPCon technology [51]. - The company developed the world's first industrial standard size photovoltaic module with a peak power of 808W, breaking the 800W barrier [52]. - The company has successfully developed high-temperature battery cells that can operate in environments exceeding 40 degrees Celsius, achieving a lifespan comparable to standard cells at 25 degrees Celsius [116]. - The company has developed and successfully mass-produced 306Ah and 314Ah battery cells for energy storage systems, which are now being utilized in self-developed battery modules [116]. Financial Health - The company's total assets at the end of the reporting period amounted to 12,000,000,000 RMB, with a 21.41% share of overseas assets [162]. - The company's cash and cash equivalents at the end of the period were 3,914,872,696.69 RMB, with significant portions pledged as collateral [162]. - The company's total liabilities increased by 141.88% to 7,363,088,708.71 RMB, primarily due to an increase in long-term borrowings due within one year [161].

天合光能股份有限公司2025 年第一季度报告 证券代码：688599 证券简称：天合光能 转债代码：118031 转债简称：天 23 转债 单位：元 币种：人民币 | 项目 | | 本报告期比上 | | | --- | --- | --- | --- | | | 本报告期 | 上年同期 | 年同期增减变 | | | | | 动幅度(%) | | 营业收入 | 14,335,076,784.40 | 18,255,937,037.92 | -21.48 | | 归属于上市公司股东的净利润 | -1,319,686,059.24 | 515,738,782.58 | -355.88 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | -1,373,418,308.79 | 447,238,367.14 | -407.09 | | 经营活动产生的现金流量净额 | -835,973,694.13 | -4,391,037,059.36 | 不适用 | 天合光能股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完 ...

Financial Performance - Operating revenue for Q1 2025 was CNY 209,602,506.82, down 26.28% from CNY 284,309,844.38 in Q1 2024[10] - Net profit attributable to shareholders for Q1 2025 was CNY 5,838,680.16, a decline of 41.24% compared to CNY 9,931,547.83 in the same period last year[10] - Total operating revenue for Q1 2025 was ¥209.60 million, a decrease of 26.3% compared to ¥284.31 million in Q1 2024[38] - Net profit for Q1 2025 was ¥5.84 million, a decline of 41.5% from ¥9.92 million in Q1 2024[39] - The company's total profit for Q1 2025 was approximately ¥2.06 million, down from ¥11.34 million in Q1 2024, reflecting a decrease of about 81.8%[42] Cash Flow - The net cash flow from operating activities increased by 155.41% to CNY 39,311,230.88, compared to a negative cash flow of CNY 70,949,432.04 in Q1 2024[10] - The net cash flow from operating activities was $8,393,425.38, a significant improvement compared to a net outflow of $78,804,482.05 in the previous period[47] - Total cash outflow from operating activities amounted to $262,237,142.15, down from $366,317,963.12 year-over-year[47] - The cash flow from financing activities for Q1 2025 was negative at approximately -¥42.00 million, compared to -¥42.26 million in Q1 2024, showing a slight improvement[45] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 757,312,611.39, a decrease of 3.46% compared to the end of 2024[10] - The company's total liabilities to assets ratio decreased to 15.27% from 18.95% year-over-year[10] - The total liabilities decreased from CNY 148,669,835.46 to CNY 115,668,371.51, a reduction of about 22.19%[32] - Current assets totaled CNY 475,001,642.08, down from CNY 501,359,228.85, indicating a decrease of about 5.25%[29] Shareholder Information - The largest shareholder, Yao Hong, holds 22,855,369 shares, representing 13.95% of the total shares[17] - Zheng Gang, another significant shareholder, holds 7,850,000 shares, accounting for 4.79% of the total shares[18] - The total number of shares held by the top ten shareholders is 59,801,282, which constitutes 36.51% of the total shares[18] Research and Development - Research and development expenses decreased by 51.06% to CNY 1,132,626.58, attributed to reduced material requisition during the reporting period[12] - Research and development expenses for Q1 2025 were approximately ¥1.04 million, a decrease from ¥1.99 million in Q1 2024, reflecting a reduction of about 47.9%[42] Legal and Compliance - The company received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws on March 21, 2025[26] - The company has no ongoing litigation or arbitration matters during the reporting period[22] - The company has fulfilled all disclosed commitments without any overdue or violations[25] Other Financial Metrics - The weighted average return on equity based on net profit attributable to shareholders was 0.91%, down from 1.31% in the previous year[10] - Basic earnings per share for Q1 2025 were ¥0.04, compared to ¥0.05 in Q1 2024[40] - The company reported a financial expense of -¥835,943.23 in Q1 2025, an improvement from -¥1,030,544.23 in Q1 2024[38]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 407,961,034.96, a decrease of 4.25% compared to CNY 426,068,533.52 in the same period last year[3] - Net profit attributable to shareholders was CNY 8,518,174.22, down 81.52% from CNY 46,099,895.98 year-on-year[3] - Basic and diluted earnings per share were both CNY 0.02, reflecting an 81.82% decrease from CNY 0.11 in the same period last year[3] - Total operating revenue for Q1 2025 was CNY 407,961,034.96, a decrease of 4.6% compared to CNY 426,068,533.52 in Q1 2024[19] - Net profit for Q1 2025 was CNY 8,518,174.22, a decline of 81.5% from CNY 46,099,895.98 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.02, down from CNY 0.11 in Q1 2024[21] Research and Development - R&D investment totaled CNY 44,937,664.51, representing an increase of 101.67% compared to CNY 22,283,293.95 in the previous year, accounting for 11.02% of operating revenue[3] - R&D expenses rose significantly to CNY 44,937,664.51 in Q1 2025, compared to CNY 22,283,293.95 in Q1 2024, reflecting a 101.5% increase[20] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 143,963,575.72, a significant improvement from a negative cash flow of CNY -39,060,029.41 in the previous year[3] - Cash received from sales of goods and services in Q1 2025 was CNY 431,234,586.13, an increase of 6.8% from CNY 403,766,822.99 in Q1 2024[23] - The net cash flow from operating activities was $143,963,575.72, a significant improvement compared to a net outflow of $39,060,029.41 in the previous period[24] - Cash inflows from operating activities were $553,657,962.04, an increase from $431,348,761.67 in the previous period, indicating growth in operational efficiency[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,549,065,939.54, an increase of 2.61% from CNY 7,356,705,041.15 at the end of the previous year[3] - Total liabilities increased to CNY 2,220,582,213.29, compared to CNY 2,043,723,276.03 in the previous period[16] - Non-current liabilities totaled CNY 667,384,101.49, an increase from CNY 500,947,884.87[16] - The company reported a total equity of CNY 5,328,483,726.25, slightly up from CNY 5,312,981,765.12[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 18,195[10] - The top shareholder, Zong Yanmin, holds 30.09% of the shares, totaling 129,302,726 shares[10] Government Support - The company received government subsidies amounting to CNY 6,000,000, which are expected to have a sustained impact on its profits[5] Current Assets - The company reported a total current assets of RMB 3,350,082,734.55 as of March 31, 2025, an increase from RMB 3,124,652,583.59 on December 31, 2024, representing a growth of approximately 7.24%[14] - Cash and cash equivalents increased to RMB 1,474,765,516.80 from RMB 1,239,198,322.57, reflecting a growth of about 19.00%[14] - Accounts receivable slightly rose to RMB 529,991,511.75 from RMB 520,263,327.64, indicating a marginal increase of 1.40%[14] - Inventory levels were reported at RMB 1,032,851,809.31, showing a slight increase from RMB 1,021,875,768.82, which is a growth of approximately 1.00%[14] Fixed Assets - The company’s long-term equity investments decreased to RMB 25,397,436.83 from RMB 26,899,414.16, a decline of about 5.58%[14] - Fixed assets were valued at RMB 3,573,533,264.25, down from RMB 3,614,761,253.75, representing a decrease of approximately 1.14%[14] Strategic Direction - The company has not reported any significant new product launches or technological advancements during the reporting period[13] - There are no updates on market expansion or mergers and acquisitions in the recent financial report[13] - The company has not indicated any changes in its strategic direction or new strategies implemented in the current reporting period[13] Financial Statement Reliability - The financial statements are unaudited, which may affect the reliability of the reported figures[14]

Financial Performance - The company's operating revenue for Q1 2025 was ¥91,423,973.13, representing an increase of 11.75% compared to ¥81,812,580.71 in the same period last year[4]. - The net profit attributable to shareholders was ¥1,504,070.84, a significant recovery from a loss of ¥36,471,708.61 in the previous year[4]. - The net cash flow from operating activities improved to ¥9,694,526.65, up from a negative cash flow of ¥53,262,841.06 in the same period last year[4]. - The basic and diluted earnings per share improved to ¥0.003, recovering from a loss of ¥0.084 per share in the same period last year[4]. - Total operating revenue for Q1 2025 reached ¥91,423,973.13, an increase of 11.6% compared to ¥81,812,580.71 in Q1 2024[28]. - Net profit for Q1 2025 was ¥1,398,207.37, a significant recovery from a net loss of ¥36,640,808.15 in Q1 2024[29]. - Total comprehensive income for Q1 2025 was ¥1,794,476.63, contrasting with a total comprehensive loss of ¥38,293,841.23 in Q1 2024[29]. Research and Development - Research and development expenses totaled ¥73,584,391.53, an increase of 11.25% from ¥66,140,705.16, accounting for 80.49% of operating revenue[5]. - The company is focusing on high-quality growth and increasing R&D investment to support technological innovation[12]. - R&D expenses rose to ¥69,354,841.80, representing an increase of 9.0% from ¥63,091,569.46 in the same period last year[28]. - Research and development expenses increased to CNY 51,535,716.25 in Q1 2025, compared to CNY 44,626,845.94 in Q1 2024, reflecting a growth of approximately 15.4%[40]. Assets and Liabilities - Total assets decreased by 1.50% to ¥2,428,636,748.94 from ¥2,465,703,479.40 at the end of the previous year[5]. - As of March 31, 2025, the total assets amounted to RMB 2,428,636,748.94, while total liabilities were RMB 448,187,131.23[24]. - The company's total assets decreased from CNY 2,708,159,701.69 as of December 31, 2024, to CNY 2,688,528,529.52 as of March 31, 2025, representing a decline of approximately 0.73%[36]. - The company's total liabilities decreased from CNY 555,245,640.01 as of December 31, 2024, to CNY 522,787,740.82 as of March 31, 2025, indicating a decline of approximately 5.83%[38]. - The total current liabilities decreased from CNY 435,466,595.31 as of December 31, 2024, to CNY 413,857,477.78 as of March 31, 2025, a reduction of approximately 4.93%[38]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,350[9]. - The board of directors underwent changes, with Zhang Wei elected as an independent director[16]. - The company has not engaged in any share lending or borrowing activities among the top shareholders[11]. - The company approved a share repurchase plan, intending to buy back shares at a price not exceeding RMB 30 per share, with a total fund of no less than RMB 20 million and no more than RMB 40 million[19]. - A total of 1,300,070 shares were repurchased, accounting for 0.30% of the total share capital, with an average repurchase price of RMB 15.39 per share, totaling RMB 20,007,759.10[19]. - The company completed the first vesting period of the 2023 restricted stock incentive plan, with 126,900 shares listed for circulation, increasing the total share capital to 433,931,345 shares[21]. Market and Competitive Position - The company continues to focus on enhancing its market competitiveness through technological development solutions, which have shown rapid growth[7]. - The company plans to expand its product market and enhance its core competitiveness in the industry[12]. - Domestic revenue accounted for 76.24% of the main business income, totaling 69.52 million RMB, while international revenue made up 23.76%, amounting to 21.67 million RMB[15]. - EDA software licensing generated 69.36 million RMB, constituting 76.07% of the main business revenue[15]. - The semiconductor device characteristic testing system business generated 8.06 million RMB, representing 8.84% of the main business revenue[15]. Cash Flow and Investment Activities - The company experienced a net cash outflow from investing activities of ¥4,042,070.15 in Q1 2025, compared to a larger outflow of ¥22,983,479.73 in Q1 2024[33]. - The company reported cash outflows from operating activities of $122,548,459.22 in Q1 2025, up from $71,900,850.09 in Q1 2024, indicating a 70% increase in operational expenses[44]. - The company received $2,193,000,000.00 from investment recoveries in Q1 2025, indicating strong investment performance[44]. - The company reported a significant increase in fair value gains, with CNY 14,070,098.15 recognized in Q1 2025, compared to a loss of CNY 22,062,016.88 in Q1 2024[41].

四川天微电子股份有限公司 2024年度业绩快报暨业绩预告更正公告 证券代码：688511 证券简称：天微电子 公告编号：2025-015 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川天微电子股份有限公司（以下简称"公司"）于 2025 年 1 月 18 日和 2025 年 2 月 28 日在《上海证券报》《中国证券报》《证券日报》《证券时报》 及上海证券交易所网站（www.sse.com.cn）披露了公司《2024 年年度业绩预亏公 告》和《2024 年度业绩快报》，现对相关内容修正如下，财务数据未经会计师 事务所审计，具体以公司将来披露的 2024 年年度报告为准，提请投资者注意投 资风险。 | 项目 | 修正前 （业绩预 | 本报告期 | 修正后 | | 修正后 的增减 变动幅 | | --- | --- | --- | --- | --- | --- | | | | 修正前 | | 上年同期 | | | | | （业绩快报） | | | | | | 告） | | | | 度（％） | | 营业总收入 | 不适 ...

Financial Performance - The company reported a revenue of 77.76 million yuan for the year 2024, a decrease of 44.65% year-over-year[4]. - The net profit attributable to the parent company was -29.16 million yuan, representing a decline of 158.66% compared to the previous year[4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was -34.83 million yuan, down 222.86% year-over-year[4]. - The decline in revenue was primarily due to decreased demand for the company's main product, the fire suppression and explosion suppression system, influenced by macroeconomic policies affecting the automotive industry[4]. - The company will not distribute cash dividends or issue bonus shares for the fiscal year 2024, considering its performance and future funding needs[9]. - The company reported a net profit attributable to the parent company of -29,157,332.80 RMB for the fiscal year 2024, with undistributed profits amounting to 146,779,422.64 RMB[178]. - The company plans no cash dividends, stock bonuses, or capital reserve transfers for the 2024 profit distribution[178]. Research and Development - The company increased its R&D investment, with R&D expenses accounting for 28.29% of revenue, up 16.87 percentage points from the previous year[26]. - The company applied for 13 new invention patents in 2024, with 2 patents granted, increasing its total to 21 active patents[38]. - The company is actively exploring the application of artificial intelligence in the security protection sector, focusing on multi-scenario applications[38]. - Research and development investment for the year was 21.997 million yuan, an increase of 37.12%, accounting for 28.29% of total revenue[40]. - The company has developed its fifth-generation fire extinguishing and explosion suppression system, achieving key performance indicators comparable to international products[77]. - The company continues to increase R&D investment in various projects, including general collection drive devices and UV optical detector technology[199]. Market and Product Development - The company is actively expanding its civilian product market, leveraging over 20 years of accumulated technology in real-time detection and intelligent control[42]. - A new AI-based electric vehicle safety protection system has been developed, featuring automatic fire alarm and extinguishing capabilities[43]. - The company is expanding into the civilian market, leveraging military technology for customized solutions in various sectors, but faces risks from macroeconomic factors[88]. - The company plans to expand its civil product market by leveraging over 20 years of accumulated core technologies, aiming to enhance competitiveness and influence in the civil market, particularly in the renewable energy sector[132]. - The company has established a comprehensive research and production technology platform for nuclear and biochemical protection systems, expanding its product applications across various military platforms[58]. Risks and Challenges - The company is at risk of delisting as it reported a negative net profit and revenue below 100 million yuan, which triggers delisting warnings under the Shanghai Stock Exchange rules[7]. - The company faces risks related to temporary price adjustments for military products, which could adversely impact revenue if significant reductions occur[5]. - The company anticipates a risk of further delays or changes in fundraising projects due to external uncertainties and has postponed the expected completion date to July 30, 2026[98]. - The company faces risks related to fluctuations in commissioned research project income, which is dependent on the number and scale of projects completed in a given period[87]. - The company is exposed to risks from potential reductions in national defense spending, which could impact military orders and profitability[95]. Governance and Management - The company has established a modern corporate governance structure, enhancing the operation mechanisms of the shareholders' meeting, board of directors, supervisory board, and management[188]. - The board of directors consists of 8 members, including 3 independent directors, ensuring compliance with legal requirements and effective decision-making[139]. - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making and operations, thereby safeguarding its autonomy[139]. - The company has proposed a three-year shareholder return plan for 2024-2026, reflecting a commitment to enhancing shareholder value[147]. - The company has appointed new independent directors, enhancing its governance structure and oversight capabilities[147]. Environmental and Social Responsibility - The company invested 3.41 million yuan in environmental protection during the reporting period[190]. - The company has achieved a 100% compliance rate in environmental management goals, ensuring zero accidents in safety and environmental protection[196]. - The company actively promotes ESG awareness among employees and integrates ESG work into its business philosophy[185]. - The company emphasizes data privacy protection and ensures compliance in product R&D and application[200].

广东利元亨智能装备股份有限公司2024 年年度报告 公司代码：688499 公司简称：利元亨 广东利元亨智能装备股份有限公司 2024 年年度报告 1/320 广东利元亨智能装备股份有限公司2024 年年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 □是 √否 三、重大风险提示 受动力锂电下游市场产能过剩影响，公司部分客户缩减或取消设备投资计划，同时行业竞争 加剧进一步压缩公司锂电设备订单的毛利率空间。尽管公司通过控本降费减少期间费用总额，但 受营收下滑影响，期间费用率仍处于较高水平，叠加银行借款及票据贴现规模扩大带来的财务费 用增长，进一步加重经营负担。此外，行业下行周期内部分项目验收周期拉长，导致公司在客户 现场的人力成本投入增加，下游客户面临阶段性经营困难导致现金流相对紧张，回款周期延长， 促使公司计提大额资产减值损失和信用减值损失，多重因素叠加导致公司经营业绩持续承压。未 来，若公司不能及时有效地应对上述不利因素的影响，公司经营业绩将 ...

广东利元亨智能装备股份有限公司2025 年第一季度报告 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人周俊雄、主管会计工作负责人高雪松及会计机构负责人（会计主管人员）赵恒保证季 度报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 证券代码：688499 证券简称：利元亨 广东利元亨智能装备股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 √适用 □不适用 单位:元 币种:人民币 | 非经常性损益项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动性资产处置损益，包括已计提资产减值 | -22,688.95 | | | 准备的冲销部分 | | | | 计入当期损益的政府补助，但与公司正常经营 | 3,471,145.81 | | | 业务密切相关、符合国家政 ...

Financial Performance - The company reported a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion into shares [8]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development [6]. - In 2024, the company's operating revenue was CNY 274,850,777.34, a decrease of 42.77% compared to CNY 480,220,256.00 in 2023 [24]. - The net profit attributable to shareholders was a loss of CNY 19,981,182.92 in 2024, down 120.02% from a profit of CNY 99,828,173.71 in 2023 [24]. - The net cash flow from operating activities decreased by 49.00% to CNY 56,563,516.68 in 2024, compared to CNY 110,908,655.20 in 2023 [27]. - The company's total assets at the end of 2024 were CNY 1,053,411,101.81, down 8.39% from CNY 1,149,858,761.63 at the end of 2023 [24]. - The company reported a decrease in net assets attributable to shareholders by 9.37% to CNY 810,050,019.65 at the end of 2024 [24]. - The company faced increased competition and reduced customer investment willingness, impacting revenue negatively [26]. - The company’s revenue decreased due to fluctuations in downstream market demand and increased competition, leading to a decline in operating income [141]. Research and Development - Research and development expenses accounted for 14.70% of operating revenue in 2024, an increase of 7.79 percentage points from 6.91% in 2023 [25]. - The total R&D investment for the year reached ¥40,411,899.21, an increase of 21.81% compared to the previous year [111]. - The company submitted 146 new patent applications during the reporting period, including 21 invention patent applications [39]. - The company has received multiple accolades for its products, including recognition as the first domestic product in various categories from 2017 to 2024, highlighting its innovation and industry leadership [70]. - The company has established a comprehensive R&D system across eight major modules, enhancing its innovation and talent development efforts [124]. - The company has developed numerous core technologies in automated production, including high-speed multi-channel feeding technology and medical soft catheter shaping technology, which are leading in the domestic market [123]. - The company is actively engaged in the research and development of GLP-1 drugs to capitalize on the growing market [103]. Operational Risks and Compliance - The company faces potential operational risks, which are detailed in the report, emphasizing the need for investor caution [6]. - The audit report from Tianjian Accounting Firm confirmed a standard unqualified opinion, ensuring the accuracy of the financial statements [7]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity [10]. - The company has not violated decision-making procedures for external guarantees, maintaining compliance with regulations [10]. - The company has established a comprehensive internal control system and governance mechanism to improve risk management and ensure compliance with legal regulations [40]. Market Trends and Industry Insights - The domestic medical consumables industry is experiencing continuous growth, driven by factors such as an aging population and increasing healthcare expenditures, with a projected steady growth trend [65]. - The intelligent manufacturing equipment industry in China is benefiting from strong government support and the integration of new information technologies, leading to rapid market growth and expansion opportunities [64]. - The demand for intelligent production equipment in the medical consumables sector is increasing due to stricter government regulations and rising labor costs, creating a favorable market environment for intelligent equipment manufacturers [66]. - The medical device market is experiencing a slowdown in growth, with investment amounts declining year-on-year [142]. Strategic Initiatives and Future Plans - The company has outlined its future plans and development strategies, which are subject to investment risks and do not constitute a commitment to investors [9]. - The company plans to invest in the "Annual Production of 35 Units of Medical Equipment Intelligent Equipment Expansion Project" to enhance production efficiency and supply capacity, utilizing part of the raised funds for this initiative [190]. - The company aims to become a global leader in medical consumables automation, focusing on enhancing technology levels and developing intelligent equipment to improve assembly efficiency and product quality for downstream manufacturers [188]. - The company intends to expand its market presence in Europe, the Americas, and developing countries, aiming to increase product market penetration and share [194]. Investor Relations and Governance - The company actively engages in investor relations to enhance communication and improve its image in the capital market [40]. - The company will strengthen investor relations management to protect minority shareholders' rights and ensure compliance with relevant laws and regulations [196]. - The company plans to optimize organizational management to enhance operational efficiency and competitiveness through improved governance structures and decision-making mechanisms [198].